Branched oligonucleotides
AssigneeUniversity of Massachusetts
InventorsAnastasia Khvorova, Matthew Hassler, Julia Alterman, Bruno Miguel da Cruz Godinho
Life of this patent
Estimating the term…
Abstract
Provided herein are branched oligonucleotides exhibiting efficient and specific tissue distribution, cellular uptake, minimum immune response and off-target effects, without formulation.
Claims23
A branched oligonucleotide compound, capable of mediating RNA silencing in a neuronal cell, comprising two or more nucleic acid sequences, wherein the nucleic acid sequences (N) are connected to one another by one or more moieties selected from a linker (L), a spacer (S) and optionally a branching point (B),
- wherein each nucleic acid sequence is double-stranded and comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand each have a 5′ end and a 3′ end, and wherein the sense strand and the antisense strand each comprises >80% chemically-modified nucleotides,
- wherein the nucleotides at positions 1 and 2 from the 5′ end of the sense and antisense strands are connected to adjacent nucleotides via phosphorothioate linkages,
- wherein each antisense strand comprises at least 15 contiguous nucleotides, wherein each sense strand comprises at least 15 contiguous nucleotides and has complementarity to the antisense strand, and wherein the antisense strand has complementarity to a target mRNA in the neuronal cell, and
- wherein the antisense strand is complementary to a target mRNA in a neuronal cell.
A branched oligonucleotide compound capable of mediating RNA silencing in a cell, comprising two or more nucleic acid sequences, wherein the nucleic acid sequences (N) are connected to one another by one or more moieties selected from a linker (L), a spacer (S) and optionally a branching point (B),
- wherein each nucleic acid sequence is double-stranded and comprises a sense strand and an antisense strand, wherein the sense strand and the antisense strand each have a 5′ end and a 3′ end, and wherein the sense strand and the antisense strand each comprises >80% chemically-modified nucleotides,
- wherein the nucleotides at positions 1 and 2 from the 5′ end of the sense and antisense strands are connected to adjacent nucleotides via phosphorothioate linkages,
- wherein each antisense strand comprises at least 15 contiguous nucleotides, and has complementarity to a target,
- wherein each sense strand comprises at least 15 contiguous nucleotides and has complementarity to the antisense strand, and
- wherein the compound comprises 5-20 phosphorothioated bonds.
Dependencies are inferred from the claim text.